Leerink Partnrs Upgrades Monopar Therapeutics (NASDAQ:MNPR) to “Strong-Buy”

Monopar Therapeutics (NASDAQ:MNPR) was upgraded by investment analysts at Leerink Partnrs to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other analysts also recently issued reports on MNPR. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Wednesday, October 8th. HC Wainwright set a $105.00 target price on shares of Monopar Therapeutics and gave the stock a “buy” rating in a research note on Monday, September 29th. Chardan Capital lifted their price target on shares of Monopar Therapeutics from $85.00 to $100.00 and gave the company a “buy” rating in a research report on Sunday. Leerink Partners initiated coverage on shares of Monopar Therapeutics in a report on Monday. They issued an “outperform” rating and a $115.00 price objective on the stock. Finally, Jones Trading upgraded shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, October 10th. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Monopar Therapeutics has a consensus rating of “Buy” and a consensus target price of $108.10.

Monopar Therapeutics Stock Performance

NASDAQ:MNPR opened at $83.08 on Monday. Monopar Therapeutics has a one year low of $16.25 and a one year high of $105.00. The stock has a market cap of $512.60 million, a PE ratio of -24.95 and a beta of 1.35. The stock has a 50 day moving average price of $74.57 and a 200 day moving average price of $50.40.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.12. As a group, analysts predict that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Transactions at Monopar Therapeutics

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 550,229 shares of the stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $63.61, for a total value of $35,000,066.69. Following the sale, the insider owned 272,026 shares of the company’s stock, valued at $17,303,573.86. This trade represents a 66.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Monopar Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of MNPR. Vanguard Group Inc. raised its stake in Monopar Therapeutics by 140.7% in the third quarter. Vanguard Group Inc. now owns 208,218 shares of the company’s stock valued at $17,005,000 after buying an additional 121,729 shares in the last quarter. Affinity Asset Advisors LLC purchased a new position in shares of Monopar Therapeutics in the 1st quarter valued at about $2,257,000. Geode Capital Management LLC raised its position in shares of Monopar Therapeutics by 99.7% during the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock worth $3,468,000 after acquiring an additional 48,379 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in Monopar Therapeutics during the first quarter worth approximately $673,000. Finally, Jane Street Group LLC acquired a new position in Monopar Therapeutics in the first quarter valued at approximately $377,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.